Rezultati

eNauka >  Rezultati >  Preliminary analysis of a phase II, multicenter, randomized, active-control study to evaluate the efficacy and safety of eganelisib (IPI 549) in combination with nivolumab compared to nivolumab monotherapy in patients with advanced urothelial carcinoma.
Naziv: Preliminary analysis of a phase II, multicenter, randomized, active-control study to evaluate the efficacy and safety of eganelisib (IPI 549) in combination with nivolumab compared to nivolumab monotherapy in patients with advanced urothelial carcinoma.
Autori: Tomczak, Piotr; Popovic, Lazar S  ; Barthelemy, Philippe; Janicic, Aleksander; Fernandez, Elena Sevillano; Borchiellini, Delphine; Aglietta, Massimo; Maroto, Jose; Carnot, Aurelien; O'Connell, Brenda;
Zizlsperger, Nora; Zhang, Halle Huihong; Valderrama, Begona P;
Godina: 2021
Publikacija: JOURNAL OF CLINICAL ONCOLOGY
ISSN: 0732-183X Journal of Clinical Oncology Pretraži identifikator
Tip rezultata: Konferencijski rad
Kolacija: vol. 39 br. 6 str. 436-436
DOI: 10.1200/JCO.2021.39.6_suppl.436
WoS-ID: 000636801500438
URI: https://enauka.gov.rs/handle/123456789/799082
Izvor metapodataka: (Preuzeto iz Nasi u WoS)
Napomena: ASCO Genitourinary Cancers Symposium (GU ASCO), ELECTR NETWORK, FEB 11-13, 2021
M-kategorija: 
Mp kategorija će biti prikazana naknadno.

7
OpenCitations
13
WEB OF SCIENCETM
Alt metrika
Dimensions
Unpaywall

Google ScholarTM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.